Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Ophthalmic Drug

PUBLISHER: Visiongain | PRODUCT CODE: 1952850

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 1952850

Ophthalmic Drugs Market Report 2026-2036

PUBLISHED:
PAGES: 393 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 6090
PDF (Team License - Up to 6 Users)
USD 7210
PDF (Site License)
USD 8470
PDF (Enterprise License - Includes Free Datasets)
USD 10703

Add to Cart

Description

Table of Contents

List of Tables

The global Ophthalmic Drugs market is projected to grow at a CAGR of 7.9% by 2036.

The Ophthalmic Drugs Market Report 2026-2036 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Technological Innovation Driving Market Expansion

Rapid technological progress across biologics, gene therapies, and digital health platforms is reshaping competitive dynamics within ophthalmology. Continued acceleration in the development of advanced biologic therapies and gene-based interventions is positioning these modalities as strategic focal points for investment, signalling a potential shift in future market leadership toward companies capable of translating complex science into scalable treatments. At the same time, anti-VEGF agents remain central to therapeutic pipelines, reflecting sustained clinical and commercial confidence in their efficacy across retinal disorders.

Artificial intelligence-enabled platforms are also emerging as a transformative force, attracting strong interest from strategic acquirers and investors due to their broad applicability in disease detection, diagnostics, and treatment monitoring. Significant capital inflows are supporting innovation across key high-burden indications including age-related macular degeneration, diabetic macular Oedema, retinal vein occlusion, and dry eye disease, underscoring the sector's focus on high-impact therapeutic areas. Beyond pharmaceuticals, evolving patient lifestyles and increasing visual-correction needs are sustaining growth in optical products; while eyeglasses continue to dominate consumer vision care, rising demand for contact lenses is prompting manufacturers to strengthen portfolio diversification and technology integration strategies.

What would be the Impact of US Trade Tariffs on the Global Ophthalmic Drugs Market?

US trade tariffs would primarily affect the global ophthalmic drugs market through structural shifts in sourcing strategy, pricing dynamics, and capital allocation rather than immediate demand disruption. Ophthalmic drug manufacturing, particularly for generics and sterile injectables, depends on globally integrated supply chains for active pharmaceutical ingredients, packaging components, and specialised manufacturing inputs. Tariff imposition on pharmaceutical imports or intermediates into the United States could increase procurement costs and introduce uncertainty into long-term supply contracts.

For multinational companies, this may accelerate regional manufacturing diversification and localisation strategies to mitigate exposure. Smaller manufacturers with concentrated export models could face greater financial strain, potentially leading to consolidation within the generics segment. In the medium term, trade-related cost pressures may influence pricing negotiations with payers and distributors, particularly in price-sensitive markets. While high-value patented biologics may be less directly affected, sustained tariff friction could reshape competitive positioning and supply resilience across the broader ophthalmic drugs ecosystem.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the ophthalmic drugs market evolving?
  • What is driving and restraining the ophthalmic drugs market?
  • How will each ophthalmic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
  • How will the market shares for each ophthalmic drugs submarket develop from 2026 to 2036?
  • What will be the main driver for the overall market from 2026 to 2036?
  • Will leading ophthalmic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2036, and which geographical region will lead the market in 2036?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the ophthalmic drugs projects for these leading companies?
  • How will the industry evolve during the period between 2026 and 2036? What are the implications of
  • ophthalmic drugs projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the ophthalmic drugs market?
  • Where is the ophthalmic drugs market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the ophthalmic drugs market today, and over the next 10 years:

  • Our 393-page report provides 146 tables and 228 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2036 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2036, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

  • Indication
  • Retinal Disorders
  • Age-related Macular Degeneration (AMD)
  • Diabetic Retinopathy/Diabetic Macular Oedema
  • Other Retinal Disorders
  • Infection/Inflammation/Allergy
  • Glaucoma
  • Dry Eye
  • Others
  • Type
  • Prescription Drugs
  • OTC Drugs
  • Route of Administration
  • Topical
  • Parenteral
  • Distribution Channel
  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Drug Type
  • Branded Drugs
  • Generic Drugs
  • Drug Class
  • Anti-VEGF Agents
  • Anti-Glaucoma Drugs
  • Anti-Inflammatory & Anti-Infective Drugs
  • Anti-Allergy Drugs
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 26 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Switzerland
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Singapore
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles for some of the leading companies in the Ophthalmic Drugs Market, 2026 to 2036, with a focus on this segment of these companies' operations.

  • Leading companies and the potential for market growth
  • AbbVie Inc.
  • Alcon
  • Apellis Pharmaceuticals
  • Bayer AG
  • Bausch + Lomb Corporation
  • Breye Therapeutics ApS
  • EyeBio
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Nicox
  • Novartis AG
  • Novaliq GmbH
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • SpliceBio
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Overall world revenue for Ophthalmic Drugs Market, 2026 to 2036 in terms of value the market will surpass US$40.0 billion in 2026, our work calculates. We predict strong revenue growth through to 2036. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Ophthalmic Drugs Market, 2026 to 2036 report help you?
  • In summary, our 390+ page report provides you with the following knowledge:
  • Revenue forecasts to 2036 for Ophthalmic Drugs Market 2026 to 2036, with forecasts for Indication, Type, Route of Administration, Distribution Channel, Drug Type, Drug Class, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2036 for five regional and 26 key national markets - See forecasts for the Ophthalmic Drugs Market, 2026 to 2036 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 20 of the major companies involved in the Ophthalmic Drugs Market, 2026 to 2036.
  • Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Show more
Product Code: PHA1383

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Ophthalmic Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Rising Frequency and Occurrence of Eye-related Conditions
      • 3.3.1.2 Technological Advancements and Innovations
      • 3.3.1.3 Increasing Prevalence of Diabetes
      • 3.3.1.4 Presence of Strong Emerging Pipeline Drugs
      • 3.3.1.5 Growth of Biologics and Anti-VEGF Agents
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High Treatment Cost and Lack of Insurance Coverage
      • 3.3.2.2 Lack of Awareness Regarding the Available Treatment Options
      • 3.3.2.3 Safety Concerns Leading Slow Uptake
      • 3.3.2.4 Patent Expiry of Blockbuster Drugs
      • 3.3.2.5 Impact of Elevated R&D Expenses and Patent Loss on Popular Pharmaceuticals
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Rise in Investment in Research and Development
      • 3.3.3.2 Rise in Geriatric Population
      • 3.3.3.3 Emergence of Digital Health Solutions and Telemedicine
      • 3.3.3.4 Growing Regulatory Support for Innovation in the Ophthalmic Sector
      • 3.3.3.5 E-Commerce and Online Pharmacies Unlock New Market Opportunities
  • 3.4 U.S. Tariffs: What's the Impact on Global Ophthalmic Drugs Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
    • 3.4.3 Why V-Shaped Recovery?
      • 3.4.3.1 Impact from Tariffs
      • 3.4.3.2 Market Dynamics and Demand Recovery
      • 3.4.3.3 Policy and Funding Support
      • 3.4.3.4 Timeframe for Recovery
    • 3.4.4 U-Shaped Recovery Scenario
      • 3.4.4.1 Why U-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 L Shaped Recovery Scenario
      • 3.4.5.1 Why L-Shaped Recovery?
      • 3.4.5.2 Impact from Tariffs
      • 3.4.5.3 Market Dynamics and Demand Recovery
      • 3.4.5.4 Policy and Funding Support
      • 3.4.5.5 Timeframe for Recovery
    • 3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
    • 3.4.7 Impact of U.S. and China Trade War on Ophthalmic Drugs Market
    • 3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 Ophthalmic Drugs Market Analysis by Indication

  • 4.1 Key Findings
  • 4.2 Indication Segment: Market Attractiveness Index
  • 4.3 Ophthalmic Drugs Market Size Estimation and Forecast by Indication
  • 4.4 Retinal Disorders
    • 4.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
    • 4.4.3 Market Forecast by Retinal Disorders, 2026-2036 (US$ Billion, AGR %)
      • 4.4.3.1 Age-related Macular Degeneration (AMD)
      • 4.4.3.2 Diabetic Retinopathy / Diabetic Macular Edema
      • 4.4.3.3 Other Retinal Disorders
  • 4.5 Infection/Inflammation/Allergy
    • 4.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)
  • 4.6 Glaucoma
    • 4.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.6.2 Market Share by Region, 2026 & 2036 (%)
  • 4.7 Dry Eye Disease
    • 4.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.7.2 Market Share by Region, 2026 & 2036 (%)
  • 4.8 Others
    • 4.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.8.2 Market Share by Region, 2026 & 2036 (%)

5 Ophthalmic Drugs Market Analysis by Type

  • 5.1 Key Findings
  • 5.2 Type Segment: Market Attractiveness Index
  • 5.3 Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 5.4 Prescription Drugs
    • 5.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 OTC Drugs
    • 5.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)

6 Ophthalmic Drugs Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 6.4 Topical
    • 6.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Parenteral
    • 6.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)

7 Ophthalmic Drugs Market Analysis by Distribution Channel

  • 7.1 Key Findings
  • 7.2 Distribution Channel Segment: Market Attractiveness Index
  • 7.3 Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 7.4 Hospital Pharmacies
    • 7.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Drug Stores
    • 7.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 Online Pharmacies
    • 7.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)

8 Ophthalmic Drugs Market Analysis by Drug Type

  • 8.1 Key Findings
  • 8.2 Drug Type Segment: Market Attractiveness Index
  • 8.3 Ophthalmic Drugs Market Size Estimation and Forecast by Drug Type
  • 8.4 Branded Drugs
    • 8.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Generic Drugs
    • 8.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)

9 Ophthalmic Drugs Market Analysis by Drug Class

  • 9.1 Key Findings
  • 9.2 Drug Class Segment: Market Attractiveness Index
  • 9.3 Ophthalmic Drugs Market Size Estimation and Forecast by Drug Class
  • 9.4 Anti-VEGF Agents
    • 9.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 9.4.2 Market Share by Region, 2026 & 2036 (%)
  • 9.5 Anti-Glaucoma Drugs
    • 9.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 9.5.2 Market Share by Region, 2026 & 2036 (%)
  • 9.6 Anti-Inflammatory & Anti-Infective Drugs
    • 9.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 9.6.2 Market Share by Region, 2026 & 2036 (%)
  • 9.7 Anti-Allergy Drugs
    • 9.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 9.7.2 Market Share by Region, 2026 & 2036 (%)
  • 9.8 Others
    • 9.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 9.8.2 Market Share by Region, 2026 & 2036 (%)

10 Ophthalmic Drugs Market Analysis by Region

  • 10.1 Key Findings
  • 10.2 Regional Market Size Estimation and Forecast

11 North America Ophthalmic Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 North America Ophthalmic Drugs Market Attractiveness Index
  • 11.3 North America Ophthalmic Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 11.4 North America Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 11.5 North America Ophthalmic Drugs Market Size Estimation and Forecast by Indication
  • 11.6 North America Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 11.7 North America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.8 North America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 11.9 North America Ophthalmic Drugs Market Size Estimation and Forecast by Drug Type
  • 11.10 North America Ophthalmic Drugs Market Size Estimation and Forecast by Drug Class
  • 11.11 U.S. Ophthalmic Drugs Market Analysis
  • 11.12 Canada Ophthalmic Drugs Market Analysis

12 Europe Ophthalmic Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Europe Ophthalmic Drugs Market Attractiveness Index
  • 12.3 Europe Ophthalmic Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 12.4 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 12.5 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Indication
  • 12.6 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 12.7 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.8 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 12.9 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Drug Type
  • 12.10 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Drug Class
  • 12.11 Germany Ophthalmic Drugs Market Analysis
  • 12.12 UK Ophthalmic Drugs Market Analysis
  • 12.13 France Ophthalmic Drugs Market Analysis
  • 12.14 Italy Ophthalmic Drugs Market Analysis
  • 12.15 Spain Ophthalmic Drugs Market Analysis
  • 12.16 The Netherlands Ophthalmic Drugs Market Analysis
  • 12.17 Switzerland Ophthalmic Drugs Market Analysis
  • 12.18 Rest of Europe Ophthalmic Drugs Market Analysis

13 Asia Pacific Ophthalmic Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
  • 13.3 Asia Pacific Ophthalmic Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 13.4 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 13.5 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Indication
  • 13.6 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 13.7 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.8 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 13.9 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Drug Type
  • 13.10 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Drug Class
  • 13.11 Japan Ophthalmic Drugs Market Analysis
  • 13.12 China Ophthalmic Drugs Market Analysis
  • 13.13 India Ophthalmic Drugs Market Analysis
  • 13.14 Singapore Ophthalmic Drugs Market Analysis
  • 13.15 Malaysia Ophthalmic Drugs Market Analysis
  • 13.16 South Korea Ophthalmic Drugs Market Analysis
  • 13.17 Australia Ophthalmic Drugs Market Analysis
  • 13.18 Rest of Asia Pacific Ophthalmic Drugs Market Analysis

14 Latin America Ophthalmic Drugs Market Analysis

  • 14.1 Key Findings
  • 14.2 Latin America Ophthalmic Drugs Market Attractiveness Index
  • 14.3 Latin America Ophthalmic Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 14.4 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 14.5 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Indication
  • 14.6 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 14.7 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 14.8 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 14.9 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Drug Type
  • 14.10 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Drug Class
  • 14.11 Brazil Ophthalmic Drugs Market Analysis
  • 14.12 Mexico Ophthalmic Drugs Market Analysis
  • 14.13 Argentina Ophthalmic Drugs Market Analysis
  • 14.14 Chile Ophthalmic Drugs Market Analysis
  • 14.15 Rest of Latin America Ophthalmic Drugs Market Analysis

15 MEA Ophthalmic Drugs Market Analysis

  • 15.1 Key Findings
  • 15.2 MEA Ophthalmic Drugs Market Attractiveness Index
  • 15.3 MEA Ophthalmic Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 15.4 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 15.5 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Indication
  • 15.6 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 15.7 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 15.8 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 15.9 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Drug Type
  • 15.10 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Drug Class
  • 15.11 GCC Ophthalmic Drugs Market Analysis
  • 15.12 South Africa Ophthalmic Drugs Market Analysis
  • 15.13 Rest of MEA Ophthalmic Drugs Market Analysis

16 Company Profiles

  • 16.1 Strategic Outlook
  • 16.2 Novartis AG
    • 16.2.1 Company Snapshot
    • 16.2.2 Company Overview
    • 16.2.3 Financial Analysis
      • 16.2.3.1 Net Revenue, 2020-2025
      • 16.2.3.2 Regional Market Shares, 2025
      • 16.2.3.3 Business Segment Market Shares, 2025
      • 16.2.3.4 R&D Expense, 2020-2025
    • 16.2.4 Product Benchmarking
    • 16.2.5 Strategic Outlook
  • 16.3 Bayer AG
    • 16.3.1 Company Snapshot
    • 16.3.2 Company Overview
    • 16.3.3 Financial Analysis
      • 16.3.3.1 Net Revenue, 2020-2024
      • 16.3.3.2 Regional Market Shares, 2024
      • 16.3.3.3 Business Segment Market Shares, 2024
      • 16.3.3.4 R&D Expense, 2020-2024
    • 16.3.4 Product Benchmarking
    • 16.3.5 Strategic Outlook
  • 16.4 Pfizer Inc.
    • 16.4.1 Company Snapshot
    • 16.4.2 Company Overview
    • 16.4.3 Financial Analysis
      • 16.4.3.1 Revenue, 2020-2024
      • 16.4.3.2 R&D Expense, 2020-2024
      • 16.4.3.3 Regional Market Shares, 2024
      • 16.4.3.4 Business Segment Market Shares, 2024
    • 16.4.4 Product Benchmarking
  • 16.5 Bausch + Lomb Corporation
    • 16.5.1 Company Snapshot
    • 16.5.2 Company Overview
    • 16.5.3 Financial Analysis
      • 16.5.3.1 Revenue, 2020-2024
      • 16.5.3.2 R&D Expense, 2020-2024
      • 16.5.3.3 Business Segment Market Shares, 2024
    • 16.5.4 Product Benchmarking
    • 16.5.5 Strategic Outlook
  • 16.6 Santen Pharmaceutical Co., Ltd.
    • 16.6.1 Company Snapshot
    • 16.6.2 Company Overview
    • 16.6.3 Financial Analysis
      • 16.6.3.1 Revenue, 2020-2025
      • 16.6.3.2 Regional Market Shares, 2025
    • 16.6.4 Product Benchmarking
    • 16.6.5 Strategic Outlook
  • 16.7 Johnson & Johnson Services, Inc.
    • 16.7.1 Company Snapshot
    • 16.7.2 Company Overview
    • 16.7.3 Financial Analysis
      • 16.7.3.1 Revenue, 2020-2025
      • 16.7.3.2 Regional Market Shares, 2025
      • 16.7.3.3 Business Segment Market Shares, 2025
      • 16.7.3.4 R&D Expense, 2020-2025
    • 16.7.4 Product Benchmarking
  • 16.9 Regeneron Pharmaceuticals Inc.
    • 16.9.1 Company Snapshot
    • 16.9.2 Company Overview
    • 16.9.3 Financial Analysis
      • 16.9.3.1 Revenue, 2020-2025
      • 16.9.3.2 R&D Expense, 2020-2025
    • 16.9.4 Product Benchmarking
    • 16.9.5 Strategic Outlook
  • 16.10 AbbVie Inc.
    • 16.10.1 Company Snapshot
    • 16.10.2 Company Overview
    • 16.10.3 Financial Analysis
      • 16.10.3.1 Revenue, 2020-2025
      • 16.10.3.2 Regional Market Shares, 2025
      • 16.10.3.3 Business Segment Market Shares, 2025
      • 16.10.3.4 R&D Expense, 2020-2025
    • 16.10.4 Product Benchmarking
    • 16.10.5 Strategic Outlook
  • 16.11 F. Hoffmann-La Roche Ltd
    • 16.11.1 Company Snapshot
    • 16.11.2 Company Overview
    • 16.11.3 Financial Analysis
      • 16.11.3.1 Revenue, 2020-2024
      • 16.11.3.2 Business Segment Market Shares, 2024
      • 16.11.3.3 R&D Expense, 2020-2024
    • 16.11.4 Product Benchmarking
    • 16.11.5 Strategic Outlook
  • 16.12 Teva Pharmaceutical Industries Ltd.
    • 16.12.1 Company Snapshot
    • 16.12.2 Company Overview
    • 16.12.3 Financial Analysis
      • 16.12.3.1 Revenue, 2020-2025
      • 16.12.3.2 Regional Market Shares, 2025
      • 16.12.3.3 R&D Expense, 2020-2025
    • 16.12.4 Product Benchmarking
    • 16.12.5 Strategic Outlook
  • 16.13 Apellis Pharmaceuticals
    • 16.13.1 Company Snapshot
    • 16.13.2 Company Overview
    • 16.13.3 Financial Analysis
      • 16.13.3.1 Revenue, 2020-2024
    • 16.13.4 Product Benchmarking
  • 16.14 Novaliq GmbH
    • 16.14.1 Company Snapshot
    • 16.14.2 Company Overview
    • 16.14.3 Product Benchmarking
    • 16.14.4 Strategic Outlook
  • 16.15 EyeBio
    • 16.15.1 Company Snapshot
    • 16.15.2 Company Overview
    • 16.15.3 Product Benchmarking
    • 16.15.4 Strategic Outlook
  • 16.17 SpliceBio
    • 16.17.1 Company Snapshot
    • 16.17.2 Company Overview
    • 16.17.3 Product Benchmarking
    • 16.17.4 Strategic Outlook
  • 16.18 Breye Therapeutics ApS
    • 16.18.1 Company Snapshot
    • 16.18.2 Company Overview
    • 16.18.3 Product Benchmarking
    • 16.18.4 Strategic Outlook
  • 16.19 Nicox
    • 16.19.1 Company Snapshot
    • 16.19.2 Company Overview
    • 16.19.3 Financial Analysis
      • 16.19.3.1 Net Revenue, 2020-2024
    • 16.19.5 Product Benchmarking
    • 16.19.6 Strategic Outlook
  • 16.20 Alcon
    • 16.20.1 Company Snapshot
    • 16.20.2 Company Overview
    • 16.20.3 Financial Analysis
      • 16.20.3.1 Net Revenue, 2020-2024
      • 16.20.3.2 Business Segment Market Shares, 2024
      • 16.20.3.3 Regional Market Shares, 2024
      • 16.20.3.4 R&D Expense, 2020-2024
    • 16.20.4 Product Benchmarking
    • 16.20.5 Strategic Outlook
  • 16.21 Viatris Inc.
    • 16.21.1 Company Snapshot
    • 16.21.2 Company Overview
    • 16.21.3 Financial Analysis
      • 16.21.3.1 Net Revenue, 2020-2024
      • 16.21.3.2 Regional Market Shares, 2024
      • 16.21.3.3 R&D Expense, 2020-2024
    • 16.21.4 Product Benchmarking
    • 16.21.5 Strategic Outlook
  • 16.22 Sun Pharmaceutical Industries Ltd.
    • 16.22.1 Company Snapshot
    • 16.22.2 Company Overview
    • 16.22.3 Financial Analysis
      • 16.22.3.1 Net Revenue, 2020-2025
      • 16.22.3.2 R&D Expense, 2020-2025
    • 16.22.4 Product Benchmarking

17 Conclusion and Recommendations

  • 17.1 Concluding Remarks from Visiongain
  • 17.2 Recommendations for Market Players
Show more
Product Code: PHA1383

List of Tables

  • Table 1 Ophthalmic Drugs Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
  • Table 2 Ophthalmic Drugs Market: Product Pipeline
  • Table 3 Ophthalmic Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): 'V' Shaped Recovery
  • Table 4 Ophthalmic Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): 'U' Shaped Recovery
  • Table 5 Ophthalmic Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): 'L' Shaped Recovery
  • Table 6 Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 7 Retinal Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 8 Retinal Disorders Segment by Type Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 9 Infection/Inflammation/Allergy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 10 Glaucoma Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 11 Dry Eye Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 12 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 13 Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 14 Prescription Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 15 OTC Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 16 Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 17 Topical Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 18 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 19 Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 20 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 21 Drug Stores Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 22 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 23 Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 24 Branded Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 25 Generic Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 26 Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 27 Anti-VEGF Agents Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 28 Anti-Glaucoma Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 29 Anti-Inflammatory & Anti-Infective Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 30 Anti-Allergy Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 31 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 32 Ophthalmic Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 33 North America Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 34 North America Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 35 North America Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 36 North America Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 37 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 38 North America Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 39 North America Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 40 U.S. Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 41 Canada Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 42 Europe Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 43 Europe Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 44 Europe Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 45 Europe Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 46 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 47 Europe Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 48 Europe Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 49 Germany Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 50 UK Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 51 Italy Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 52 Spain Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 53 The Netherlands Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 54 Switzerland Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 55 Rest of Europe Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 56 Asia Pacific Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 57 Asia Pacific Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 58 Asia Pacific Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 59 Asia Pacific Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 60 Asia Pacific Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 61 Asia Pacific Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 62 Asia Pacific Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 63 Japan Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 64 China Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 65 India Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 66 Singapore Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 67 Malaysia Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 68 South Korea Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 69 Australia Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 70 Rest of Asia Pacific Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 71 Latin America Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 72 Latin AmericaOphthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 73 Latin America Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 74 Latin AmericaOphthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 75 Latin AmericaOphthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 76 Latin AmericaOphthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 77 Latin AmericaOphthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 78 Brazil Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 79 Mexico Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 80 Argentina Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 81 Chile Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 82 Rest of Latin America Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 83 MEA Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 84 MEA Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 85 MEA Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 86 MEA Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 87 MEA Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 88 MEA Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 89 MEA Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 90 GCC Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 91 South Africa Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 92 Rest of MEA Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 93 Strategic Outlook
  • Table 94 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 Novartis AG: Product Benchmarking
  • Table 96 Novartis AG: Strategic Outlook
  • Table 97 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 Bayer AG: Product Benchmarking
  • Table 99 Bayer AG: Strategic Outlook
  • Table 100 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 101 Pfizer Inc.: Product Benchmarking
  • Table 102 Bausch + Lomb Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Bausch + Lomb Corporation: Product Benchmarking
  • Table 104 Bausch + Lomb Corporation: Strategic Outlook
  • Table 105 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 Santen Pharmaceutical Co., Ltd.: Product Benchmarking
  • Table 107 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
  • Table 108 Johnson & Johnson Services Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 Johnson & Johnson Private Limited: Product Benchmarking
  • Table 110 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Regeneron Pharmaceuticals Inc.: Product Benchmarking
  • Table 112 Regeneron Pharmaceuticals Inc.: Strategic Outlook
  • Table 113 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 114 AbbVie Inc.: Product Benchmarking
  • Table 115 AbbVie Inc.: Strategic Outlook
  • Table 116 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 117 F. Hoffmann-La Roche Ltd: Product Benchmarking
  • Table 118 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 119 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 120 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 121 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
  • Table 122 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 123 Apellis Pharmaceuticals: Product Benchmarking
  • Table 124 Novaliq GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 125 Novaliq GmbH.: Product Benchmarking
  • Table 126 Novaliq GmbH: Strategic Outlook
  • Table 127 EyeBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 128 EyeBio: Product Benchmarking
  • Table 129 EyeBio: Strategic Outlook
  • Table 130 SpliceBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 131 SpliceBio: Product Benchmarking
  • Table 132 SpliceBio: Strategic Outlook
  • Table 133 Breye Therapeutics ApS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 134 Breye Therapeutics ApS: Product Benchmarking
  • Table 135 Breye Therapeutics ApS: Strategic Outlook
  • Table 136 Nicox: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 137 Nicox: Product Benchmarking
  • Table 138 Nicox: Strategic Outlook
  • Table 139 Alcon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 140 Alcon: Product Benchmarking
  • Table 141 Alcon: Strategic Outlook
  • Table 142 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 143 Viatris Inc.: Product Benchmarking
  • Table 144 Viatris Inc.: Strategic Outlook
  • Table 145 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 146 Sun Pharmaceutical Industries Ltd.: Product Benchmarking

List of Figures

  • Figure 1 Ophthalmic Drugs Market Segmentation
  • Figure 2 Ophthalmic Drugs Market by Indication: Market Attractiveness Index
  • Figure 3 Ophthalmic Drugs Market by Type: Market Attractiveness Index
  • Figure 4 Ophthalmic Drugs Market by Route of Administration: Market Attractiveness Index
  • Figure 5 Ophthalmic Drugs Market by Distribution Channel: Market Attractiveness Index
  • Figure 6 Ophthalmic Drugs Market by Drug Type: Market Attractiveness Index
  • Figure 7 Ophthalmic Drugs Market by Drug Class: Market Attractiveness Index
  • Figure 8 Ophthalmic Drugs Market Attractiveness Index by Region
  • Figure 9 Ophthalmic Drugs Market: Market Dynamics
  • Figure 10 Ophthalmic Drugs Market: Impact Analysis
  • Figure 11 Ophthalmic Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 12 Ophthalmic Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 13 Ophthalmic Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 14 Short Term & Long-TermPlanning
  • Figure 15 Impact of U.S. and China Trade War
  • Figure 16 Most Impacted Countries
  • Figure 17 Ophthalmic Drugs Market: Porter's Five Forces Analysis
  • Figure 18 Ophthalmic Drugs Market: PEST Analysis
  • Figure 19 Ophthalmic Drugs Market Attractiveness Index by Indication
  • Figure 20 Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 21 Ophthalmic Drugs Market Share Forecast by Indication, 2026, 2031, 2036 (%)
  • Figure 22 Retinal Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 23 Retinal Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 24 Retinal Disorders Segment Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 25 Infection/Inflammation/Allergy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 26 Infection/Inflammation/Allergy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 27 Glaucoma Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 28 Glaucoma Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 29 Dry Eye Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 30 Dry Eye Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 31 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 32 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 33 Ophthalmic Drugs Market Attractiveness Index by Indication
  • Figure 34 Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 35 Ophthalmic Drugs Market Share Forecast by Type, 2026, 2031, 2036 (%)
  • Figure 36 Prescription Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 37 Prescription Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 38 OTC Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 39 OTC Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 40 Ophthalmic Drugs Market Attractiveness Index by Route of Administration
  • Figure 41 Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 42 Ophthalmic Drugs Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
  • Figure 43 Topical Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 44 Topical Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 45 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 46 Parenteral Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 47 Ophthalmic Drugs Market Attractiveness Index by Distribution Channel
  • Figure 48 Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 49 Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2026, 2031, 2036 (%)
  • Figure 50 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 51 Hospital Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 52 Drug Stores Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 53 Drug Stores Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 54 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 55 Online Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 56 Ophthalmic Drugs Market Attractiveness Index by Drug Type
  • Figure 57 Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 58 Ophthalmic Drugs Market Share Forecast by Drug Type, 2026, 2031, 2036 (%)
  • Figure 59 Branded Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 60 Branded Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 61 Generic Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 62 Generic Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 63 Ophthalmic Drugs Market Attractiveness Index by Drug Class
  • Figure 64 Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
  • Figure 65 Ophthalmic Drugs Market Share Forecast by Drug Class, 2026, 2031, 2036 (%)
  • Figure 66 Anti-VEGF Agents Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 67 Anti-VEGF Agents Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 68 Anti-Glaucoma Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 69 Anti-Glaucoma Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 70 Anti-Inflammatory & Anti-Infective Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 71 Anti-Inflammatory & Anti-Infective Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 72 Anti-Allergy Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 73 Anti-Allergy Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 74 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 75 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 76 Ophthalmic Drugs Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
  • Figure 77 Ophthalmic Drugs Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 78 Ophthalmic Drugs Market by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 79 North America Ophthalmic Drugs Market Attractiveness Index
  • Figure 80 North America Ophthalmic Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 81 North America Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 82 North America Ophthalmic Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 83 North America Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 84 North America Ophthalmic Drugs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 85 North America Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 86 North America Ophthalmic Drugs Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 87 North America Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 88 North America Ophthalmic Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 89 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 90 North America Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 91 North America Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 92 North America Ophthalmic Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 93 North America Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
  • Figure 94 North America Ophthalmic Drugs Market Share Forecast by Drug Class, 2026 & 2036 (%)
  • Figure 95 U.S. Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 96 Canada Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 97 Europe Ophthalmic Drugs Market Attractiveness Index
  • Figure 98 Europe Ophthalmic Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 99 Europe Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 100 Europe Ophthalmic Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 101 Europe Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 102 Europe Ophthalmic Drugs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 103 Europe Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 104 Europe Ophthalmic Drugs Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 105 Europe Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 106 Europe Ophthalmic Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 107 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 108 Europe Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 109 Europe Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 110 Europe Ophthalmic Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 111 Europe Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
  • Figure 112 Europe Ophthalmic Drugs Market Share Forecast by Drug Class, 2026 & 2036 (%)
  • Figure 113 Germany Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 114 UK Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 115 France Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 116 Italy Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 117 Spain Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 118 The Netherlands Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 119 Switzerland Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 120 Rest of Europe Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 121 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
  • Figure 122 Asia Pacific Ophthalmic Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 123 Asia Pacific Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 124 Asia Pacific Ophthalmic Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 125 Asia Pacific Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 126 Asia Pacific Ophthalmic Drugs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 127 Asia Pacific Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 128 Asia Pacific Ophthalmic Drugs Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 129 Asia Pacific Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 130 Asia Pacific Ophthalmic Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 131 Asia Pacific Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 132 Asia Pacific Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 133 Asia Pacific Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 134 Asia Pacific Ophthalmic Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 135 Asia Pacific Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
  • Figure 136 Asia Pacific Ophthalmic Drugs Market Share Forecast by Drug Class, 2026 & 2036 (%)
  • Figure 137 Japan Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 138 China Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 139 India Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 140 Singapore Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 141 Malaysia Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 142 South Korea Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 143 Australia Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 144 Rest of Asia Pacific Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 145 Latin America Ophthalmic Drugs Market Attractiveness Index
  • Figure 146 Latin America Ophthalmic Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 147 Latin America Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 148 Latin America Ophthalmic Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 149 Latin America Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 150 Latin America Ophthalmic Drugs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 151 Latin America Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 152 Latin America Ophthalmic Drugs Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 153 Latin America Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 154 Latin America Ophthalmic Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 155 Latin America Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 156 Latin America Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 157 Latin America Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 158 Latin America Ophthalmic Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 159 Latin America Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
  • Figure 160 Latin America Ophthalmic Drugs Market Share Forecast by Drug Class, 2026 & 2036 (%)
  • Figure 161 Brazil Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 162 Mexico Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 163 Argentina Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 164 Chole Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 165 Rest of Latin America Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 166 MEA Ophthalmic Drugs Market Attractiveness Index
  • Figure 167 MEA Ophthalmic Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 168 MEA Ophthalmic Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 169 MEA Ophthalmic Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 170 MEA Ophthalmic Drugs Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 171 MEA Ophthalmic Drugs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 172 MEA Ophthalmic Drugs Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 173 MEA Ophthalmic Drugs Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 174 MEA Ophthalmic Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 175 MEA Ophthalmic Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 176 MEA Ophthalmic Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 177 MEA Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 178 MEA Ophthalmic Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 179 MEA Ophthalmic Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 180 MEA Ophthalmic Drugs Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
  • Figure 181 MEA Ophthalmic Drugs Market Share Forecast by Drug Class, 2026 & 2036 (%)
  • Figure 182 GCC Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 183 South Africa Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 184 Rest of MEA Ophthalmic Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 185 Novartis AG: Net Revenue, 2020-2025 (US$ Million, AGR %)
  • Figure 186 Novartis AG: Regional Market Shares (%), 2025
  • Figure 187 Novartis AG: Business Segment Market Shares (%), 2025
  • Figure 188 Novartis AG: R&D Expense, 2020-2025 (US$ Million, AGR %)
  • Figure 189 Bayer AG: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 190 Bayer AG: Regional Market Shares (%), 2024
  • Figure 191 Bayer AG: Business Segment Market Shares (%), 2024
  • Figure 192 Bayer AG: R&D Expense, 2020-2024 (US$ Million, AGR %)
  • Figure 193 Pfizer Inc.:Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 194 Pfizer Inc.:R&D Expense, 2020-2024 (US$ Million, AGR %)
  • Figure 195 Pfizer Inc.: Regional Market Shares (%), 2024
  • Figure 196 Pfizer Inc.: Business Segment Market Shares (%), 2024
  • Figure 197 Bausch + Lomb Corporation:Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 198 Bausch + Lomb Corporation: R&D Expense, 2020-2024 (US$ Million, AGR %)
  • Figure 199 Bausch + Lomb Corporation.: Business Segment Market Shares (%), 2024
  • Figure 200 Santen Pharmaceutical Co., Ltd.:Annual Revenue, 2020-2025 (US$ Million, AGR %)
  • Figure 201 Santen Pharmaceutical Co., Ltd.: Regional Market Shares (%), 2025
  • Figure 202 Johnson & Johnson Services, Inc.:Annual Revenue, 2020-2025 (US$ Million, AGR %)
  • Figure 203 Johnson & Johnson Services, Inc.: Regional Market Shares (%), 2025
  • Figure 204 Johnson & Johnson Services, Inc.: Business Segment Market Shares (%), 2025
  • Figure 205 Johnson & Johnson Services Inc.: R&D Expense, 2020-2025 (US$ Million, AGR %)
  • Figure 206 Regeneron Pharmaceuticals Inc.:Annual Revenue, 2020-2025 (US$ Million, AGR %)
  • Figure 207 Regeneron Pharmaceuticals Inc: R&D Expense, 2020-2025 (US$ Million, AGR %)
  • Figure 208 AbbVie Inc.:Annual Revenue, 2020-2025 (US$ Million, AGR %)
  • Figure 209 AbbVie: Regional Market Shares (%), 2025
  • Figure 210 AbbVie: Business Segment Market Shares (%), 2025
  • Figure 211 AbbVie Inc.: R&D Expense, 2020-2025 (US$ Million, AGR %)
  • Figure 212 F. Hoffmann-La Roche Ltd:Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 213 F. Hoffmann-La Roche Ltd.: Business Segment Market Shares (%), 2024
  • Figure 214 F. Hoffmann-La Roche Ltd: R&D Expense, 2020-2024 (US$ Million, AGR %)
  • Figure 215 Teva Pharmaceutical Industries Ltd.:Annual Revenue, 2020-2025 (US$ Million, AGR%)
  • Figure 216 Teva Pharmaceutical Industries Ltd.: Regional Market Shares (%), 2025
  • Figure 217 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2020-2025 (US$ Million, AGR %)
  • Figure 218 Apellis Pharmaceuticals:Annual Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 219 Nicox: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 220 Alcon: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 221 Alcon: Business Segment Market Shares (%), 2024
  • Figure 222 Alcon: Regional Market Shares (%), 2024
  • Figure 223 Alcon: R&D Expense, 2020-2024 (US$ Million, AGR %)
  • Figure 224 Viatris Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 225 Viatris Inc.: Regional Market Shares (%), 2024
  • Figure 226 Viatris Inc.: R&D Expense, 2020-2024 (US$ Million, AGR %)
  • Figure 227 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2020-2025 (US$ Million, AGR %)

List of Companies Profiled in the Report

  • AbbVie Inc.
  • Alcon
  • Apellis Pharmaceuticals
  • Bayer AG
  • Bausch + Lomb Corporation
  • Breye Therapeutics ApS
  • EyeBio
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Nicox
  • Novartis AG
  • Novaliq GmbH
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • SpliceBio
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

List of Other Companies Mentioned in the Report

  • Adalvo Limited
  • Advanz Pharma
  • AffaMed Therapeutics
  • Alembic Pharmaceuticals
  • Alteogen
  • Alvotech
  • Amneal Pharmaceuticals
  • Apexus
  • Arctic Vision
  • Azura Ophthalmics
  • Biocon Biologics
  • Bioeq
  • Caplin Point Laboratories
  • Caplin Steriles
  • Chiesi Global Rare Diseases
  • Chong Kun Dang Pharmaceutical
  • ENTOD Pharmaceuticals
  • EssexBio
  • Eyebiotech Limited
  • Eyenovia
  • Formosa Pharmaceuticals
  • Formycon
  • Glaukos
  • Glenmark Pharmaceuticals
  • HanAll Biopharma
  • Harrow
  • Health Sciences
  • Henlius Biotech
  • Huons Co. Ltd.
  • IDB VisionCare Sdn Bhd
  • Jiangsu Hengrui Pharmaceuticals
  • Ji Xing Pharmaceuticals Limited
  • Kerun Biopharm
  • Kowa Company, Ltd.
  • Laboratoires Thea
  • Lenz Therapeutics
  • Lotus Pharmaceutical
  • LumiThera, Inc.
  • Nanomi
  • Neurotech Pharmaceuticals
  • Ocular Therapeutix
  • Ocumension Therapeutics
  • Otsuka Pharmaceutical
  • Polpharma Biologics Group BV
  • PolyActiva
  • PulseSight Therapeutics
  • RareSight
  • RemeGen
  • Re-Vana Therapeutics
  • RTW Investments, LP
  • Senju Pharmaceutical
  • Sunzen Biotech Bhd
  • Tenpoint Therapeutics
  • Unither Pharmaceuticals
  • VISUfarma
  • Whitecap Biosciences, LLC

List of Associations Mentioned in the Report

  • American Academy of Ophthalmology (AAO)
  • American Glaucoma Society (AGS)
  • American Society of Retina Specialists (ASRS)
  • Asia-Pacific Academy of Ophthalmology (APAO)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • European Glaucoma Society (EGS)
  • European Society of Ophthalmology (SOE)
  • European Society of Retina Specialists (EURETINA)
  • International Agency for the Prevention of Blindness (IAPB)
  • International Council of Ophthalmology (ICO)
  • International Dry Eye Workshop (DEWS)
  • International Ocular Inflammation Society (IOIS)
  • International Society of Ocular Oncology (ISOO)
  • Royal College of Ophthalmologists (RCOphth)
  • World Glaucoma Association (WGA)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!